Key Takeaways from the First-in-Human Study of Odronextamab in B-cell NHL

February 10, 2021

Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.

Rajat Bannerji, MD, PhD, of the Rutgers Cancer Institute of New Jersey discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma (NCT0229095).

The first-in-human phase one study is to determine the safety, tolerability, and appropriate dosage of odronextamab. The dose-escalation portion of the study is complete with results having been presented at the American Society of Hematology (ASH) Annual Meeting & Exposition 2019.

Researchers presented longer follow-up data at ASH 2020 on durable response rates and ongoing remission. According to the study, an overall response rate of 55% was achieved with all patients achieving a complete response. Of those who responded, 83% were durable responses, meaning response lasted at least 3 months. At the time of data cutoff, 1 patient had a durable response of 21 months.